Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. (Q51301791)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 June 2015

Language	Label	Description	Also known as
English	Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.	scientific article published on 6 June 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

0 references

Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Wenjia Yang

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Lingli Zhou

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Simin Zhang

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Xueyao Han

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Linong Ji

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

6 June 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

50

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

590-597

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

https://scigraph.springernature.com/pub.10.1007/s12020-015-0653-3

0 references

GLP-1: physiological effects and potential therapeutic applications

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Incretin effects on β-cell function, replication, and mass: the human perspective

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label,

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

DPP-4 inhibitors and lipids: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0653-3

21 January 2018

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/26048437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26048437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12020-015-0653-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26048437%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51301791&oldid=1446165643"